Literature DB >> 29155278

MeCP2 Expression in a Rat Model of Risky Decision Making.

Jay V Deng1, Caitlin A Orsini2, Kristy G Shimp3, Barry Setlow4.   

Abstract

Many neuropsychiatric disorders are associated with abnormal decision making involving risk of punishment, but the underlying molecular basis remains poorly understood. Methyl CpG-binding protein 2 (MeCP2) is an epigenetic factor that regulates transcription by directly binding to methylated DNA. Here, we evaluated MeCP2 expression in the context of risk-taking behaviors using the Risky Decision-making Task (RDT), in which rats make discrete choices between a small "safe" food reward and a large "risky" food reward accompanied by varying probabilities of punishment. In Experiment 1, expression of MeCP2 as assessed by immunoblotting in the medial prefrontal cortex (mPFC), but not the striatum, was inversely correlated with the degree of preference for the large, risky reward (risk taking) seven days after the last RDT test. In Experiment 2, MeCP2 expression 90 min after RDT testing, assessed using immunohistochemistry, was suppressed in both the dorsal mPFC (dmPFC) and nucleus accumbens compared to home cage controls, indicating that MeCP2 expression is modulated by RDT performance. Additional experiments revealed that RDT performance increased expression of MeCP2 phosphorylated at Ser421 (associated with neuronal activity and activation of gene expression) in dmPFC principal neurons. Finally, as in Experiment 1, lower expression of MeCP2 in the ventral mPFC was associated with greater risk taking under baseline conditions. Together, these findings indicate a complex regulatory role of MeCP2 in risky decision making, and suggest that epigenetic factors may be an important component of the molecular mechanisms underlying such decision-making processes.
Copyright © 2017 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  DNA methylation; MeCP2; decision making; epigenetics; medial prefrontal cortex; risk taking

Mesh:

Substances:

Year:  2017        PMID: 29155278      PMCID: PMC5766376          DOI: 10.1016/j.neuroscience.2017.11.016

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  34 in total

1.  Effects of acute administration of nicotine, amphetamine, diazepam, morphine, and ethanol on risky decision-making in rats.

Authors:  Marci R Mitchell; Colin M Vokes; Amy L Blankenship; Nicholas W Simon; Barry Setlow
Journal:  Psychopharmacology (Berl)       Date:  2011-06-03       Impact factor: 4.530

Review 2.  Epigenetic regulation in psychiatric disorders.

Authors:  Nadia Tsankova; William Renthal; Arvind Kumar; Eric J Nestler
Journal:  Nat Rev Neurosci       Date:  2007-05       Impact factor: 34.870

3.  Adolescent risk taking, cocaine self-administration, and striatal dopamine signaling.

Authors:  Marci R Mitchell; Virginia G Weiss; B Sofia Beas; Drake Morgan; Jennifer L Bizon; Barry Setlow
Journal:  Neuropsychopharmacology       Date:  2013-10-22       Impact factor: 7.853

4.  Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription.

Authors:  P L Jones; G J Veenstra; P A Wade; D Vermaak; S U Kass; N Landsberger; J Strouboulis; A P Wolffe
Journal:  Nat Genet       Date:  1998-06       Impact factor: 38.330

5.  Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state.

Authors:  Peter J Skene; Robert S Illingworth; Shaun Webb; Alastair R W Kerr; Keith D James; Daniel J Turner; Rob Andrews; Adrian P Bird
Journal:  Mol Cell       Date:  2010-02-26       Impact factor: 17.970

Review 6.  The story of Rett syndrome: from clinic to neurobiology.

Authors:  Maria Chahrour; Huda Y Zoghbi
Journal:  Neuron       Date:  2007-11-08       Impact factor: 17.173

Review 7.  Nothing tastes as good as skinny feels: the neurobiology of anorexia nervosa.

Authors:  Walter H Kaye; Christina E Wierenga; Ursula F Bailer; Alan N Simmons; Amanda Bischoff-Grethe
Journal:  Trends Neurosci       Date:  2013-01-18       Impact factor: 13.837

8.  Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function.

Authors:  Jifang Tao; Keping Hu; Qiang Chang; Hao Wu; Nicholas E Sherman; Keri Martinowich; Robert J Klose; Carolyn Schanen; Rudolf Jaenisch; Weidong Wang; Yi Eve Sun
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-18       Impact factor: 11.205

9.  DNA methylation signatures of mood stabilizers and antipsychotics in bipolar disorder.

Authors:  Lotte C Houtepen; Annet H van Bergen; Christiaan H Vinkers; Marco P M Boks
Journal:  Epigenomics       Date:  2016-01-21       Impact factor: 4.778

10.  MeCP2, a key contributor to neurological disease, activates and represses transcription.

Authors:  Maria Chahrour; Sung Yun Jung; Chad Shaw; Xiaobo Zhou; Stephen T C Wong; Jun Qin; Huda Y Zoghbi
Journal:  Science       Date:  2008-05-30       Impact factor: 47.728

View more
  4 in total

1.  Reward/Punishment-Based Decision Making in Rodents.

Authors:  Caitlin A Orsini; Nicholas W Simon
Journal:  Curr Protoc Neurosci       Date:  2020-09

2.  Contributions of medial prefrontal cortex to decision making involving risk of punishment.

Authors:  Caitlin A Orsini; Sara C Heshmati; Tyler S Garman; Shannon C Wall; Jennifer L Bizon; Barry Setlow
Journal:  Neuropharmacology       Date:  2018-07-20       Impact factor: 5.250

3.  Distinct relationships between risky decision making and cocaine self-administration under short- and long-access conditions.

Authors:  Caitlin A Orsini; Shelby L Blaes; Richard J Dragone; Sara M Betzhold; Alyssa M Finner; Jennifer L Bizon; Barry Setlow
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2019-10-30       Impact factor: 5.067

4.  Differential effects of glutamate N-methyl-D-aspartate receptor antagonists on risky choice as assessed in the risky decision task.

Authors:  Justin R Yates; Matthew J Horchar; Alexis L Ellis; Joy L Kappesser; Prodiges Mbambu; Tanner G Sutphin; Destiny S Dehner; Hephzibah O Igwe; Makayla R Wright
Journal:  Psychopharmacology (Berl)       Date:  2020-09-16       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.